Abstract:Background Takayasu’s arteritis (TAK) is a rare large-vessel vasculitis characterized by granulomatous inflammation in the aorta and its major branches.[1] The affected arteries may become narrowed or even occluded, resulting in ischemia of the corresponding tissue or organs and threatening patient survival.[2] However, effective treatment strategies for TAK are lacking. Although TCZ and TNF-α inhibitors are commonly applied in the treatment of refractory TAK, a formal head-to-head study evaluating their efficacy is lacking. According to retrospective studies,[3, 4] the complete response rate associated with TCZ was slightly better than those associated with TNF-α inhibitors at 6 months (70% vs. 66%; 70% vs. 61%). However, another study indicated a better 3-month complete remission rate associated with TNF-α inhibitors than with TCZ (30% vs. 18%) [5]. Thus, the data are inconclusive regarding which medication is more effective. Furthermore, the 6-month nonresponse and 12-month relapse rates associated with these treatments were approximately 25% and 19%, respectively.[3] Thus, given the inconsistent results obtained thus far in this context, we conducted this randomized, open-label, head-to-head study to compare the efficacy and safety of the TNF-α antibody adalimumab (ADA) and TCZ combined with GCs and MTX in patients with active and severe TAK. Objectives This study was aimed at investigating the efficacy and safety of adalimumab (ADA) and tocilizumab (TCZ) in patients with active and severe Takayasu arteritis (TAK) concomitantly treated with glucocorticoids (GCs) and methotrexate (MTX). Methods Forty patients were randomized into ADA and TCZ groups (n = 21 and 19, respectively). They were treated with ADA or TCZ combined with GCs and MTX, respectively. The planned follow-up duration was 12 months. The primary end point was the efficacy rate (ER) at 6 months. Results The intention to treat (ITT) population included 21 and 19 patients from the ADA and TCZ groups, respectively. In this population, the ERs at 6 months were higher in the ADA group (85.71% vs. 52.63%, P = 0.02). Similar tendencies were also noted in per-protocol set (89.47% vs. 62.50%, P = 0.06). At the 6-month time point, the percentages of patients receiving a GC dose of ≤10 mg/day and the cumulative GC dose were similar between the ADA and TCZ groups (47.37% vs. 43.75%, P = 0.83; 4200 mg vs. 4100 mg, P = 0.15, respectively). Imaging improvement or stabilization was observed in most patients in both groups (ADA vs. TCZ: 19/19 vs. 15/16, P = 0.27). Adverse event incidence was comparable between the two groups (ADA vs. TCZ: 38.10% vs. 47.37%, P = 0.55). Conclusion ADA probably was more effective than TCZ in combined treatment with GCs and MTX among patients with active and severe TAK. References [1]Group JCSJW. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 2011, 75(2):474-503. [2]Zaldivar Villon MLF, de la Rocha JAL, Espinoza LR. Takayasu Arteritis: Recent Developments. Curr Rheumatol Rep 2019, 21(9):45. [3]Mekinian A, Comarmond C, Resche-Rigon M et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015, 132(18):1693-1700. [4]Novikov PI, Smitienko IO, Moiseev SV. Tumor necrosis factor alpha inhibitors in patients with Takayasu’s arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 2013, 32(12):1827-1832. [5]Mekinian A, Resche-Rigon M, Comarmond C et al. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. J Autoimmun 2018, 91:55-60. Acknowledgements: NIL. Disclosure of Interests None Declared.

Relationship between earlier introduction of tocilizumab and glucocorticoid-sparing effects on the acute phase of adult-onset Still's disease

Effective Therapy of Tocilizumab on Systemic Juvenile Idiopathic Arthritis Associated Refractory Macrophage Activation Syndrome.

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: cases report and literature review

Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article.

Tocilizumab discontinuation after remission achievement in patients with adult-onset Still’s disease

Successful Treatment of Refractory Adult-Onset Still’s Disease with Tocilizumab Combined with Methotre-Xate:A Retrospective Study of 28 Cases

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Ruxolitinib Rescued the Macrophage Activation Syndrome in Adult-Onset Still’s Disease with Delayed Hypersensitivity Reaction to Tocilizumab

Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Clinical and immunological feature, therapeutic response and prognosis of adult onset Still's disease

Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: A case report

Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment

Effectiveness and Safety of Tocilizumab in Patients with Refractory or Severe Takayasu's Arteritis: A Prospective Cohort Study in a Chinese Population

Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder

Clinical Characterisis and Prognosis Analysis of 107 Adult Onset Still's Disease

Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus

POS0702 TREATMENT EFFICACY AND SAFETY OF ADALIMUMAB VERSUS TOCILIZUMAB COMBINED WITH METHOTREXATE AND GLUCOCORTICOIDS IN PATIENTS WITH ACTIVE AND SEVERE TAKAYASU ARTERITIS: A RANDOMIZED, OPEN-LABEL, HEAD-TO-HEAD STUDY

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome